T. Yau

The Lancet · 2014–2023

A researcher in the Science corpus: 8 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom T. Yau trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Lisa Sullivan
  2. H. B. EL‐SERAG

Who trusts T. Yau overall

  1. J. Llovet
  2. Amit G. Singal

Papers from T. Yau's perspective

Ordered by how strongly the researchers T. Yau trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
  2. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival (Hepatology)
  3. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. (The Lancet Oncology)
  4. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests (Biometrics)
  5. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (The Lancet Oncology)
  6. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (The Lancet)
  7. Presentation of multivariate data for clinical use: The Framingham Study risk score functions
  8. Modeling Survival Data Extending The Cox Model
  9. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  10. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (International Journal of Cancer)

Their papers